Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
378.96B | 372.81B | 357.78B | 322.47B | 292.11B | 268.71B | Gross Profit |
53.24B | 51.40B | 54.43B | 54.50B | 52.12B | 49.05B | EBIT |
9.62B | 8.52B | 13.74B | 7.95B | 13.31B | 13.91B | EBITDA |
14.82B | 13.68B | 18.20B | 12.35B | 17.53B | 17.12B | Net Income Common Stockholders |
5.28B | 4.61B | 8.34B | 4.31B | 8.00B | 7.18B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
12.65B | 10.99B | 11.46B | 15.72B | 12.53B | 10.85B | Total Assets |
255.59B | 253.22B | 249.73B | 228.28B | 233.00B | 230.72B | Total Debt |
81.21B | 82.92B | 79.39B | 70.73B | 76.00B | 85.04B | Net Debt |
71.14B | 74.33B | 71.19B | 57.79B | 66.59B | 77.19B | Total Liabilities |
178.47B | 177.49B | 173.09B | 156.51B | 157.62B | 161.01B | Stockholders Equity |
76.93B | 75.56B | 76.46B | 71.47B | 75.08B | 69.39B |
Cash Flow | Free Cash Flow | ||||
5.94B | 6.33B | 10.39B | 13.45B | 15.74B | 13.43B | Operating Cash Flow |
8.76B | 9.11B | 13.43B | 16.18B | 18.27B | 15.87B | Investing Cash Flow |
-6.28B | -7.61B | -20.89B | -5.05B | -5.26B | -5.53B | Financing Cash Flow |
-2.24B | -1.14B | 2.68B | -10.52B | -11.36B | -7.70B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $27.45B | 8.21 | 12.59% | ― | 8.85% | 33.30% | |
72 Outperform | $27.84B | 16.31 | 10.09% | 1.53% | 10.09% | -12.18% | |
71 Outperform | $88.87B | 15.35 | 14.24% | 1.68% | 6.63% | -3.26% | |
71 Outperform | $83.40B | 17.30 | 12.37% | 1.83% | 24.65% | 48.38% | |
69 Neutral | $275.06B | 12.68 | 24.33% | 2.77% | 8.68% | 45.24% | |
69 Neutral | $80.43B | 15.19 | 7.00% | 4.18% | 4.84% | -26.54% | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% |
At the CVS Health Corporation Annual Meeting of Stockholders held on May 15, 2025, all 13 nominees for the Board of Directors were elected for a one-year term. The stockholders approved the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2025 and the advisory approval of executive compensation. However, a stockholder proposal to reduce the threshold for stockholder rights to act by written consent was not approved.
The most recent analyst rating on (CVS) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on CVS Health stock, see the CVS Stock Forecast page.
On April 7, 2025, CVS Health announced key leadership changes effective in May 2025. Brian O. Newman was appointed as the Executive Vice President and Chief Financial Officer, succeeding Thomas F. Cowhey, who will transition to a strategic advisor role. Additionally, Amy L. Compton-Phillips was named Executive Vice President and Chief Medical Officer. These appointments are part of CVS Health’s strategy to enhance its leadership team and continue its growth in delivering health care services to millions of Americans.